Recently, BioNTech, a pharmaceutical company from the Greater Bay Area specializing in mRNA drugs, plans to go public through an IPO in Hong Kong, China. The listing could take place as early as next year, potentially raising approximately US$200 million.

Recently, Huihe Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Huihe Biotechnology") completed an A++round of financing, exclusively invested by strategic investor Shanghai Toujing Life Technology Co., Ltd. (hereinafter referred to as "Toujing Life"). Toujing Life's exclusive investment in Huihe Biotechnology is optimistic about the company's independently developed and globally leading new generation co stimulatory signal triple antibody TCE innovative drug platform (TriTE) ™）

During the 2025 European Society of Oncology (ESMO) conference, the Phase I research data of QLH12016, a androgen receptor (AR) protein degradation targeted chimeric (PROTAC) degradation agent developed by Qilu Pharmaceutical, was released in the field of metastatic castration resistant prostate cancer (mCRPC) (abstract number 2450P), bringing new hope to this difficult to treat cancer with limited treatment options and poor prognosis. As an oral AR targeted PROTAC drug, QLH12016 achieves more potent and thorough inhibition of the AR signaling pathway through protein degradation technology. Its safety and anti-tumor activity data in multi line treatment of mCRPC patients mark a crucial step towards the era of "precision degradation" in prostate cancer treatment.

On October 26, 2025, pharmaceutical giant Novartis officially announced its acquisition of Avidity Biosciences, a pioneer in the field of AOC (Antibody Oligonucleotide Conjugates), for a cash consideration of $12 billion. This 46% premium transaction marks the largest acquisition in the RNA therapy field of the year.